Client News
Filter by:
- Aug 11 2022 NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
- Jan 6 2022 Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
- Jan 4 2022 Arch Therapeutics Announces Appointment of Guy Fish to the Board
- Dec 17 2021 OncoSec Announces Changes to its Board of Directors
- Dec 14 2021 INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
- Dec 13 2021 Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
- Dec 1 2021 Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
- Nov 30 2021 INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
- Nov 16 2021 INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
- Nov 15 2021 INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference